Paris AI startup Biolevate secures €30M, expands to Boston
Biolevate, an AI firm focused on life sciences, has closed a €30 million Series A round. The funding was co-led by Orange Ventures and RAISE France. The company also announced the opening of its first U.S. office in Boston.
Sources: thenextweb.com
“The move into Boston—a hub for biotech and pharma—signals Biolevate’s push to align with major industry players, rather than just selling AI tools as a standalone product.”
What it means
Boston’s dense ecosystem of research institutions and pharmaceutical companies makes it a strategic choice for life sciences AI startups looking to embed their technology directly into drug discovery pipelines. Whether Biolevate can compete with established players like BenevolentAI or Recursion will depend on how quickly it can integrate with local partners. The Series A size suggests investors are betting on its ability to scale, but execution in a crowded market remains unproven.
Read the original reporting
The outlets below did the original reporting.
Related briefs
This brief was drafted automatically from the sources above and published under our editorial policy. Spotted an error? Tell us.